Last reviewed · How we verify
NCT06355843
Clinical Applications of Integrated PET/MR and PET/CT in the Diagnosis and Treatment of Prostate Cancer.
NA trial testing 68Ga-PSMA in Prostate Cancer in 50 participants. Suspended.
30 September 2023
Quick facts
| Lead sponsor | The First Affiliated Hospital of Anhui Medical University |
|---|---|
| Phase | NA |
| Status | Suspended |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | diagnostic |
| Enrollment | 50 |
| Start date | 28 April 2022 |
| Primary completion | 30 September 2023 |
| Estimated completion | 31 March 2027 |
| Sites | 1 location across China |
Drugs / interventions tested
- 68Ga-PSMA — full drug profile →
Conditions studied
- Prostate Cancer — all drugs for Prostate Cancer →
- Pet-ct — all drugs for Pet-ct →
Sponsor
The First Affiliated Hospital of Anhui Medical University
Who can join
Adults 18 to 75, male only, with Prostate Cancer or Pet-ct. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The goal of this study type: observational study (prospective study) is to study prostate cancer occurrence and recurrence, to specifically identify and localize tumor foci at the molecular level at an early stage, to evaluate the prognosis of patients, and to accurately stage not only intermediate- and high-risk prostate cancer patients with a primary diagnosis, but also detect recurrent foci in patients with biochemical recurrence, to restage those who have developed metastases, to assess tumor load, and to ultimately assist in determining the personalized treatment plans. The main question it aims to answer is whether 68Ga-PSMA PET/CT (PET/MR) examination is beneficial for assessing the * Accurate staging of patients with intermediate- and high-risk prostate cancer at first diagnosis; * Detecting recurrent lesions in patients with recurrent tumors for re-staging; * Assessment of tumor load; * Assessment of patient prognosis. Participants will sign an informed consent form, undergo 68Ga-PSMA PET/CT (PET/MR) before surgery or biopsy, and have regular follow-up after obtaining pathological results of surgical resection or puncture biopsy, 6 weeks after surgery or biopsy, and then every 3 months; the follow-up will include: blood PSA, whole-body bone imaging, etc.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06355843
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of 68Ga-PSMA
Trials testing the same drug.
- NCT06560905 — Preoperative Planning With PSMA-PET in Melanoma Surgery Trial · Phase 2 · recruiting
- NCT05170555 — Diagnosis of Renal Cell Carcinoma on 68Ga-PSMA PET-CT and Radioligand Therapy With 177Lu-EB-PSMA-617 · NA · unknown
- NCT05006326 — Clinical Application of 68Ga-PSMA PET/MR for Diagnosis and Staging in Hepatocellular Carcinoma · NA · unknown
- NCT04614363 — 68 Ga-PSMA for High Risk Prostate Cancer · Phase 1, PHASE2 · completed
- NCT06484361 — PET/MRI to Stage Prostate Cancer Patients · Phase 2 · recruiting
Other recruiting trials for Prostate Cancer
Currently open trials in the same condition.
- NCT06960798 — Characterizing the Genomic Landscape of Prostate Cancer in Native American Populations (NAT-Geno) · recruiting
- NCT07237269 — Abi/Pred + ADT vs ADT in PSMA-Positive, Conventionally Node-Negative Prostate Cancer · Phase 2 · recruiting
- NCT07234981 — PSMA-PET Guided De-escalation of Salvage Radiation Treatment in Recurrent Prostate Cancer · Phase 2 · recruiting
- NCT07027124 — Neoadjuvant ADT + Darolutamide With Pembrolizumab, Followed by Adjuvant Pembrolizumab in Molecularly Stratified High-Ris · Phase 2 · recruiting
- NCT07426094 — PRO-BOOST-N: Prostate-First Versus Combined Prostate and Nodal Dose Escalation in PSMA PET-Staged Node-Positive Prostate · Phase 2, PHASE3 · recruiting
Other The First Affiliated Hospital of Anhui Medical University trials
Trials by the same sponsor.
- NCT07273890 — Real-time Feedback of Red-out Within Colonoscopy Intubation · NA · not yet recruiting
- NCT07346378 — Clinical Study on the Safety and Efficacy of Temporal Interference Stimulation in the Treatment of Post-Stroke Aphasia · NA · recruiting
- NCT07247682 — Dose-escalation of Rectal Indomethacin for Preventing PEP · Phase 4 · not yet recruiting
- NCT07194109 — Remiazolam vs Propofol Total Intravenous Anesthesia on Postoperative Neurodevelopment After General Anesthesia in Childr · Phase 4 · not yet recruiting
- NCT07086287 — Evaluation of the Efficacy of rhBNP in Patients With Diuretic Resistance After Cardiac Surgery · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06355843 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by The First Affiliated Hospital of Anhui Medical University
- Last refreshed: 9 April 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06355843.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing